Ashling Wahner

Tari A. King, MD, FACS, FSSO, FASCO, discusses the importance of multidisciplinary breast cancer management and the potential to de-escalate treatment.

Samina Hirani, MD, discusses the evolving first-line treatment paradigm for patients with DLBCL and the unprecedented findings from the POLARIX trial.

Tari A. King, MD, FACS, FSSO, FASCO, discusses locoregional breast cancer management strategies and avoiding lymph node dissection in select patients.

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

Jonathan Leventhal, MD, discusses the prevalence of breast cancer treatment–associated dermatologic AEs and the need for multidisciplinary management.

Meletios A. Dimopoulos, MD, discusses the efficacy and safety of elranatamab plus daratumumab and lenalidomide in transplant-ineligible multiple myeloma.

Versamune HPV plus pembrolizumab improved OS vs historical data with pembrolizumab in HPV16-positive metastatic HNSCC with a CPS of at least 1.

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

Five experts gathered for the OncLive Peer Exchange to discuss SCLC data that continues to drive the evolving treatment paradigm.

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

The FDA issued a complete response letter for subcutaneous daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

The NCCN guidelines for NSCLC were updated to include zongertinib as a preferred subsequent therapy option for advanced or metastatic HER2-mutant NSCLC.

Martin Dreyling, MD, PhD, discusses clinical trial findings with acalabrutinib plus BR in patients with high-risk mantle cell lymphoma.

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Lung cancer experts share upcoming, potentially practice-informing clinical trials that are expected to read out in the second half of 2025.

The FDA granted accelerated approval to dordaviprone for patients at least 1 year of age with progressive H3K27M-mutated diffuse midline glioma.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

Waddah Arafat, MD, discusses the future clinical implications of the ongoing KEYNOTE-B15/EV-304 trial and the safety profile of the NIAGARA trial regimen.

Waddah Arafat, MD, discusses the treatment paradigm for MIBC and questions regarding the benefit seen with neoadjuvant chemoimmunotherapy in this setting.

Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

The FDA has issued a complete response letter for odronextamab in relapsed or refractory follicular lymphoma.

The first-in-class, allogeneic stem cell–loaded oncolytic virus CLD-201 was granted FDA fast track designation for the treatment of soft tissue sarcoma.

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.

Onvansertib plus SOC generated responses with a tolerable safety profile in patients with previously untreated RAS-mutated metastatic colorectal cancer.

Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.

Francesca Palandri, MD, PhD, discusses the results from a subgroup analysis of momelotinib vs ruxolitinib in myelofibrosis with anemia and low platelet counts.

Jyoti S. Mayadev, MD, discusses a ctDNA analysis from the CALLA study of chemoradiation with or without durvalumab in locally advanced cervical cancer.